Transfusion-transmitted infections
- PMID: 38607595
- PMCID: PMC11014835
- DOI: 10.1007/s44313-024-00014-w
Transfusion-transmitted infections
Abstract
The risk of transfusion-transmitted infection (TTI) has always existed because transfused blood products are biological materials derived from humans. To prevent TTIs, screening strategies have been developed for various infectious diseases, such as hepatitis B virus, hepatitis C virus, and human immunodeficiency virus, contributing significantly to reducing TTI globally. Nevertheless, septic transfusion reactions (STRs) due to bacterial contamination remain an unresolved issue. Various infectious diseases can be transmitted through blood products, and preventive and selective screening strategies have been applied across different regions. Although multiple strategies, including culture-based and rapid detection kit-based methods, have been introduced to overcome STRs, complete prevention has not yet been achieved. Recently, pathogen inactivation methods have been developed to eliminate non-specific organisms rather than screening specific organisms. This approach is anticipated to contribute significantly to diminishing the risk of TTIs in the future.
Keywords: Hepatitis B virus; Hepatitis C virus; Human immunodeficiency virus; Pathogen inactivation; Transfusion-transmitted infection.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy.Transfusion. 2005 Oct;45(10):1670-5. doi: 10.1111/j.1537-2995.2005.00576.x. Transfusion. 2005. PMID: 16181219
-
Implementation of amotosalen plus ultraviolet A-mediated pathogen reduction for all platelet concentrates in France: Impact on the risk of transfusion-transmitted infections.Vox Sang. 2024 Mar;119(3):212-218. doi: 10.1111/vox.13574. Epub 2023 Dec 28. Vox Sang. 2024. PMID: 38152857
-
The Mirasol Evaluation of Reduction in Infections Trial (MERIT): study protocol for a randomized controlled clinical trial.Trials. 2022 Apr 4;23(1):257. doi: 10.1186/s13063-022-06137-8. Trials. 2022. PMID: 35379302 Free PMC article.
-
Haematology patients and the risk of transfusion transmitted infection.Br J Haematol. 2018 Feb;180(4):473-483. doi: 10.1111/bjh.15030. Epub 2018 Jan 24. Br J Haematol. 2018. PMID: 29363748 Review.
-
Challenges in transfusion microbiology.Transfus Med Rev. 1993 Apr;7(2):96-103. doi: 10.1016/s0887-7963(93)70128-5. Transfus Med Rev. 1993. PMID: 8481604 Review.
Cited by
-
Intraoperative Hemoadsorption in Heart Transplant Surgery: A 5-Year Experience.J Cardiovasc Dev Dis. 2025 Mar 28;12(4):119. doi: 10.3390/jcdd12040119. J Cardiovasc Dev Dis. 2025. PMID: 40278178 Free PMC article.
-
Cell-based artificial platelet production: historical milestones, emerging trends, and future directions.Blood Res. 2025 May 27;60(1):32. doi: 10.1007/s44313-025-00071-9. Blood Res. 2025. PMID: 40423909 Free PMC article. Review.
References
-
- CfD C. Pneumocystis carinii pneumonia among persons with hemophilia A. MMWR Morb Mortal Wkly Rep. 1982;31:365–367. - PubMed
-
- Cohn C, Delaney M, Johnson ST, Katz LM, Schwartz J. Technical Manual. 21st. Bethesda: AABB; 2023.
-
- Kang JW, Shin S, Seo DH, Kang J, Ko DH, Song CE, et al. Estimation of the residual risk of transfusion-transmissible infectious agents in Korea. Korean J Blood Transfus. 2019;30:156–162. doi: 10.17945/kjbt.2019.30.2.156. - DOI
Publication types
LinkOut - more resources
Full Text Sources